U.S. patent application number 09/528506 was filed with the patent office on 2001-12-27 for effect of electric field and ultrasound for transdermal drug delivery.
Invention is credited to Kost, Joseph, Langer, Robert S., Mitragotri, Samir S., Pliquett, Uwe, Weaver, James C..
Application Number | 20010056255 09/528506 |
Document ID | / |
Family ID | 27076376 |
Filed Date | 2001-12-27 |
United States Patent
Application |
20010056255 |
Kind Code |
A1 |
Kost, Joseph ; et
al. |
December 27, 2001 |
Effect of electric field and ultrasound for transdermal drug
delivery
Abstract
Transdermal transport of molecules during sonophoresis (delivery
or extraction) can be further enhanced by application of an
electric field, for example, electroporation or iontophoresis. In a
preferred embodiment the ultrasound is low frequency ultrasound
which induces cavitation of the lipid layers of the stratum corneum
(SC). This method provides higher drug transdermal fluxes, allows
rapid control of transdermal fluxes, and allows drug delivery or
analyte extraction at lower ultrasound intensities than when
ultrasound is applied in the absence of an electric field.
Inventors: |
Kost, Joseph; (Omer, IL)
; Pliquett, Uwe; (Leipzig, DE) ; Mitragotri, Samir
S.; (Somerville, MA) ; Langer, Robert S.;
(Newton, MA) ; Weaver, James C.; (Sudbury,
MA) |
Correspondence
Address: |
Patrea L Pabst Esq
ARNALL GOLDEN & GREGORY
2700 One Atlantic Center
1201 W Peachtree Street
Atlanta
GA
30309-3450
US
|
Family ID: |
27076376 |
Appl. No.: |
09/528506 |
Filed: |
March 20, 2000 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09528506 |
Mar 20, 2000 |
|
|
|
08626021 |
Apr 1, 1996 |
|
|
|
6041253 |
|
|
|
|
08626021 |
Apr 1, 1996 |
|
|
|
08574377 |
Dec 18, 1995 |
|
|
|
5947921 |
|
|
|
|
Current U.S.
Class: |
604/22 ;
604/20 |
Current CPC
Class: |
A61N 1/0412 20130101;
A61B 5/14514 20130101; A61N 1/327 20130101; A61N 1/0428 20130101;
A61M 2037/0007 20130101; A61N 1/042 20130101; A61M 37/0092
20130101; A61K 41/0047 20130101; A61K 9/0009 20130101; A61N 1/325
20130101 |
Class at
Publication: |
604/22 ;
604/20 |
International
Class: |
A61N 001/30 |
Goverment Interests
[0002] The United States government has rights in this invention by
virtue of National Institute of Health (NIH grant GM44884) to
Robert Langer and Army Office Grant No. DAAL03-90-G0218 to James C.
Weaver.
Claims
We claim:
1. A method for enhancing transdermal transport of compounds
comprising administering to the skin an effective amount of
ultrasound in combination with an electric field.
2. The method of claim 1 wherein the ultrasound is administered at
a frequency of less than 2.5 MHz.
3. The method of claim 1 wherein the ultrasound is administered at
a frequency of 1 MHz or less.
4. The method of claim 1 wherein the intensity of the ultrasound is
less than 2.5 W/cm.sup.2.
5. The method of claim 1 wherein the intensity of the ultrasound is
less than 1.5 W/cm.sup.2.
6. The method of claim 1 wherein the ultrasound is administered
with agents enhancing solubility of the compounds to be transported
in combination with agents enhancing the fluidity of lipid
bilayers.
7. The method of claim 1 wherein the ultrasound is administered in
combination with an electric force field selected from the group
consisting of electroporation and iontophoresis.
8. The method of claim 1 wherein the compound to be transported is
a drug the patient is in need of.
9. The method of claim 1 wherein the compound to be transported is
an analyte to be measured.
10. The method of claim 1 wherein the electric field is pulsed.
11. The method of claim 1 wherein the ultrasound is pulsed.
12. An apparatus for applying ultrasound and an electric field to
skin in an amount effect to enhance transport of molecules through
the skin without damaging the skin.
Description
[0001] This is a continuation in part of U.S. Ser. No. 08/574,377
entitled "Chemical and Physical Enhancers and Ultrasound for
Transdermal Drug Delivery" filed Dec. 18, 1995 by Mark E. Johnson,
Samir S. Mitragotri, Daniel Blankschtein and Robert S. Langer.
BACKGROUND OF THE INVENTION
[0003] The present invention generally relates to improved methods
for drug delivery and measurement of analyte using ultrasound in
combination with application of an electric field.
[0004] Transdermal drug delivery (TDD) offers several advantages
over traditional delivery methods including injections and oral
delivery. When compared to oral delivery, TDD avoids
gastrointestinal drug metabolism, reduces first-pass effects, and
provides sustained release of drugs for up to seven days, as
reported by Elias, In Percutaneous Absorption:
Mechanisms--Methodology-Drag Delivery., Bronaugh, R. L., Maibach,
H. 1. (Ed), pp 1-12, Marcel Dekker, New York, 1989. The word
"transdermal" is used herein as a generic term. However, in
actuality, transport of drugs occurs only across the epidermis
where the drug is absorbed in the blood capillaries. When compared
to injections, TDD eliminates the associated pain and the
possibility of infection. Theoretically, the transdermal route of
drug administration could be advantageous in the delivery of many
therapeutic proteins, because proteins are susceptible to
gastrointestinal degradation and exhibit poor gastrointestinal
uptake, proteins such as interferons are cleared rapidly from the
blood and need to be delivered at a sustained rate in order to
maintain their blood concentration at a high value, and transdermal
devices are easier to use than injections.
[0005] Ultrasound has been shown to enhance transdermal transport
of low-molecular weight drugs (molecular weight less than 500)
across human skin, a phenomenon referred to as sonophoresis (Levy,
J. Clin Invest. 1989, 83, 2974-2078; Langer, R., In "Topical Drug
Bioavailability, Bioequivalence, and Penetration"; pp. 91-103, Shah
V. P., M.H.I., Eds. (Plenum: New York, 1993); Frideman, R. M.,
`Interferons: A Primer`, Academic Press, New York, 1981)).
Ultrasound has been shown to create cavitation within the SC, which
disorders the lipid bilayers and increases drug transport (Walters,
In Transdermal Drug Delivery: Developmental Issues and Research
Initiatives, Hadraft, ed. (Marcel Dekker, 1989) pp. 197-233).
[0006] U.S. Pat. No. 4,309,989 to Fahim and U.S. Pat. No. 4,767,402
to Kost, et al., disclose various ways in which ultrasound has been
used to achieve transdermal drug delivery. Sonophoresis has been
shown to enhance transdermal transport of various drugs. Although a
variety of ultrasound conditions have been used for sonophoresis,
the most commonly used conditions correspond to the therapeutic
ultrasound (frequency in the range of 1 MHz -3 MHz, and intensity
in the range of 0-2 W/cm.sup.2) (Kost, In Topical Drug
Bioavailability Bioequivalence and Penetration, pp. 91-103,
Maibach, H. I., Shah, V. P. (Ed) Plenum Press, New York, 1993; U.S.
Pat. No. 4,767,402 to Kost, et al.).
[0007] In spite of these advantages, very few drugs and no proteins
or peptides are currently administered transdermally for clinical
applications because of the low skin permeability to drugs.
Application of therapeutic ultrasound does not induce transdermal
transport of high-molecular weight proteins. It is a common
observation that the typical enhancement induced by therapeutic
ultrasound is less than ten-fold. In many cases, no enhancement of
transdermal drug transport has been observed upon ultrasound
application. This low permeability is attributed to the stratum
comeum (SC), the outermost skin layer which consists of flat, dead
cells filled with keratin fibers (keratinocytes) surrounded by
lipid bilayers. The highly-ordered structure of the lipid bilayers
confers an impermeable character to the SC (Flynn, G. L., In
Percutaneous Absorption: Mechanisms--Methodology-Drug Delivery.;
Bronaugh, R. L., Maibach, H. I. (Ed), pages 27-53, Marcel Dekker,
New York, 1989).
[0008] A variety of approaches have been suggested to enhance
transdermal transport of drugs. These include: i) use of chemicals
to either modify the skin structure or to increase the drug
concentration in the transdermal patch (Junginger, et al. In "Drug
Permeation Enhancement"; Hsieh, D. S., Eds., pp. 59-90 (Marcel
Dekker, Inc. New York 1994; Bumette, R. R. In Developmental Issues
and Research Initiatives; Hadgraft J., G., R. H., Eds., Marcel
Dekker: 1989; pp. 247-288); ii) applications of electric fields to
create transient transport pathways [electroporation] (Prausnitz
Proc. Natl. Acad. Sci. USA 90, 10504-10508 (1993); Walters, K. A.,
in Transdermal Drug Delivery: Developmental Issues and Research
Initiatives, Ed. Hadgraft J., Guy, R. H., Marcel Dekker, 1989) or
to increase the mobility of charged drugs through the skin
[iontophoresis], and iii) application of ultrasound [sonophoresis].
Various approaches including chemical enhancers [Walters, K. A., in
Transdermal Drug Delivery: Developmental Issues and Research
Initiatives, Hadgraft J., Guy, R. H., Marcel Dekker: New York
(1989)], ultrasound [Levy et al., J. Clin. Invest., 83: 2074-2078
(1989); Mitragotri et al., J. Pharm. Sci, 84:697-706 (1995)] and
electrical enhancement [Prausnitz et al. Proc. Natl. Acad. Sci.
USA, 90:10504-10508 (1993); Pliquett et al., Pharmaceutical
Research, 12:549-555 (1995); Chizmadzhev et al., Biophysical J.
68:749-765 (1995); Bumette (1989)] have been suggested to enhance
transdermal drug transport. In some cases, high strengths of the
physico-chemical forces (for example, electricity, ultrasound) are
required to deliver a given drug dose transdermally. However, the
highest strength of these physico-chemical forces that can be used
is limited by their adverse physiological effects.
[0009] Chemical enhancers have been found to increase transdermal
drug transport via several different mechanisms, including
increased solubility of the drug in the donor formulation,
increased partitioning into the SC, fluidization of the lipid
bilayers, and disruption of the intracellular proteins (Kost and
Langer, In Topical Drug Bioavailability, Bioequivalence, and
Penetration; Shah and Maibech, ed. (Plennum, N.Y. 1993) pp. 91-103
(1993)). U.S. Pat. No. 5,445,611 to Eppstein, et al., describes
enhancement of ultrasound using the combination of chemical
enhancers with modulation of the frequency, intensity, and/or phase
of the ultrasound to induce a type of pumping action. However, the
intensity and frequencies used in the examples are quite high,
which generates heat and decreasing transport over time.
[0010] Electroporation is believed to work in part by creating
transient pores in the lipid bilayers of the SC (Burnett (1989)).
Iontophoresis provides an electrical driving force to move
compounds. Electroporation involves application of electric field
pulses that create transient aqueous pathways in lipid bilayer
membranes, causing a temporary alteration of skin structure. While
occurrence of aqueous pores may allow transdermal permeation of
neutral molecules by diffusion, the transport of charged molecules
during pulsing occurs predominantly by electrophoresis and
electroosmosis.
[0011] Accordingly, a better selection of ultrasound parameters is
needed to induce a higher enhancement of transdermal drug transport
by sonophoresis. Moreover, although efficacy to some degree has
been observed using ultrasound for transport of other compounds,
the efficiency of transport under conditions acceptable to patients
has not been achieved.
[0012] It is therefore an object of the present invention to
provide a method and means for enhancing transdermal transport.
[0013] It is a further object of the present invention to provide
methods for using ultrasound in combination with other means of
enhancement for drug delivery and collection of analyte in an
efficient, practical manner.
SUMMARY OF THE INVENTION
[0014] Transdermal transport of molecules during sonophoresis
(delivery or extraction) can be further enhanced by the application
of an electric field, for example, by iontophoresis or
electroporation. In a preferred embodiment, the ultrasound is low
frequency ultrasound which induces cavitation of the lipid layers
of the stratum corneum (SC). This method i) provides higher
transdermal fluxes, ii) allows rapid control of transdermal fluxes,
and iii) allows drug delivery or analyte extraction at lower
ultrasound intensities than required in the absence of an electric
field. Still further enhancement can be obtained using a
combination of chemical enhancers and/or magnetic field with the
electric field and ultrasound.
[0015] Examples using two model compounds, calcein and
sulphorhodamine, demonstrate that transdermal transport enhancement
induced by simultaneous application of ultrasound and electric
pulses is higher than that due to electric pulses or ultrasound
alone. Application of ultrasound reduces the threshold voltage
required for the onset of calcein and sulphorhodamine transport in
the presence of electric fields.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1A is a graph of sulforhodamine flux/.mu.g/(cm.sup.2h)
over time (seconds) for electroporation of sulforhodamine, followed
by application of electroporation in combination with ultrasound.
After 400 sec of passive diffusion, pulsed ultrasound (1 MHz, 20%
duty cycle, 2.5-2.9 W/cm.sup.2) was turned on for 2750 sec. The
ultrasound was turned off at 2750 sec. High voltage pulsing was
turned on at 6900 sec for 1 hour (10,500 sec end of electroporation
pulsing). Ultrasound (1 MHz, 0.8 cm.sup.2 20% duty cycle, 2.5-2.9
W/cm.sup.2) was turned on again at 14,310 sec, electroporation was
turned on again at 15,200 sec while the pulsed ultrasound was on.
At 16,440 sec the ultrasound wave was changed from pulsed to
continuous while the electroporation continued.
[0017] FIG. 1B is a graph of the time variation of calcein flux in
the presence of electric fields alone (X) and during simultaneous
application of ultrasound and electric field (0) (1 MHz, 1.4
W/cm.sup.2, continuous application, and electric field, 100 V
across the skin, exponentially decaying pulse with a time constant
(.tau.) of 1 millisecond, one pulse applied every minute).
Ultrasound was ON all the time (O). Electric voltage was turned ON
at time 0 and was turned OFF at 1 hour in both the case (O as well
as X). Presented as means and S.D. of at least three
repetitions.
[0018] FIG. 1C. Time variation of sulphorhodamine flux in the
presence of electric field alone (X) and during simultaneous
application of ultrasound and electric field (O) (1 MHz, 1.4
W/cm.sup.2, continuous application, and electric field, 100 V
across the skin, exponentially decaying pulse with a time constant
(.tau.) of 1 millisecond, one pulse applied every minute).
Ultrasound was ON all the time (O). Electric voltage was turned ON
at time O and was turned OFF at 1 hour in both the case (O as well
as X). Presented as means and S.D. of at least three
repetitions.
[0019] FIGS. 2A and 2B are graphs of calcein and sulphorhodamine
flux over time (hours), respectively. Skin samples were exposed
continuously to electroporation (electric field (750 V across the
chamber, equivalent to approximately 210-230 volts across the skin,
exponentially decaying pulse with a time constant (.tau.) of 1
millisecond, one pulse applied every minute) and continuous
ultrasound (1 MHz, 0.8 cm.sup.2, 2 W/cm.sup.2) (o) and controls (x)
where the skin was exposed to electric fields alone.
[0020] FIG. 3 is a graph of the variation of the transdermal
sulphorhodamine flux with the applied electric field (100 V across
the skin, exponentially decaying pulse with a time constant (.tau.)
of 1 millisecond, one pulse applied every minute) in the presence
(O) and absence (X) of ultrasound. Presented as means and S.D. of
at least three repetitions.
[0021] FIG. 4. Variation of the normalized transdermal calcein and
sulphorhodamine flux under a variety of conditions. A--in the
presence of electric field alone, B--in the presence of ultrasound
and electric field, C--in the presence of ultrasound alone, D--in
the absence of ultrasound and electric field. The transdermal
calcein and sulphorhodamine fluxes have been normalized by the
corresponding fluxes prior to application of ultrasound, that is,
at the end of 0.5 hours. This was done to assist comparison of the
relative charges in transdermal flux under different
conditions.
DETAILED DESCRIPTION OF THE INVENTION
[0022] Sonophoresis:
[0023] As used herein, sonophoresis is the application of
ultrasound to the skin, alone or in combination with chemical
enhancers, iontophoresis, electroporation, magnetic force fields,
mechanical pressure fields or electrical fields, to facilitate
transport of a compound through the skin. In one embodiment, a
drug, alone or in combination with a carrier, penetration enhancer,
lubricant, or other pharmaceutically acceptable agent for
application to the skin, is applied to the skin. In another
embodiment, the compound is an analyte such as glucose which is
present in a body fluid and extracted by application of the
ultrasound, alone or in combination with other forces and/or
chemical enhancers.
[0024] Ultrasound is defined as sound at a frequency of between 20
kHz and 10 MHz, with intensities of between greater than 0 and 3
W/cm.sup.2. Ultrasound is preferably administered at frequencies of
less than or equal to about 2.5 MHz to induce cavitation of the
skin to enhance transport. As used herein, "low frequency"
sonophoresis is ultrasound at a frequency that is less than 1 MHz,
more typically in the range of 20 to 40 KHz, which can be applied
continuously or in pulses, for example, 100 msec pulses every
second, at intensities in the range of between zero and 1
W/cm.sup.2, more typically between 12.5 mW/cm.sup.2 and 225
mW/cm.sup.2. Exposures are typically for between 1 and 10 minutes,
but may be shorter and/or pulsed. It should be understood that
although the normal range of ultrasound begins at 20 kHz, one could
achieve comparable results by varying the frequency to slightly
more or less than 20 kHz. The intensity should not be so high as to
raise the skin temperature more than about one to two degrees
Centigrade.
[0025] Application of low-frequency (20 kHz) ultrasound
dramatically enhances transdermal transport of drugs. Transdermal
transport enhancement induced by low-frequency ultrasound was found
to be as much as 1000-fold higher than that induced by therapeutic
ultrasound (frequency in the range of 1 MHz-3 MHz, and intensity in
the range of 0-2 W/cm.sup.2). Another advantage of low-frequency
sonophoresis as compared to therapeutic ultrasound is that the
former can induce transdermal transport of drugs which do not
passively permeate across the skin. Application of low-frequency
ultrasound appears to induce cavitation inside as well as outside
the skin. Cavitation occurring at either location may cause
disordering of the SC lipids. In addition, oscillations of
cavitation bubbles may result in significant water penetration into
the disordered lipid regions. -This may cause the formation of
aqueous channels through the intercellular lipids of the SC. This
allows permeants to transport across the disordered lipid domains,
then across keratinocytes and the entire SC. This transport pathway
may result in an enhanced transdermal transport as compared to
passive transport because the diffusion coefficients of permeants
through water, which is likely to primarily occupy the channels
generated by ultrasound, are up to 1000-fold higher than those
through the ordered lipid bilayers, and the transport path length
of these aqueous channels may be much shorter (by a factor of up to
25) than that through the tortuous intercellular lipids in the case
of passive transport.
[0026] Many ultrasound devices are available commercially which can
be used in the method described herein. For example, the ultrasonic
devices used by dentists to clean teeth have a frequency of between
about 25 and 40 KHz. Commercially available portable ultrasound
tooth-brushes make use of a small sonicator contained within the
tooth-brush (Sonex International Corporation). This sonicator is
portable and operates on rechargeable batteries. Small pocket-size
sonicators carried by patients and used to "inject" drugs whenever
required could be readily adapted from these devices. In addition,
these devices could be combined with sensors that can monitor drug
concentrations in the blood to formulate a self-controlled drug
(insulin, for example) delivery method that can decrease the
attention required by the patient.
[0027] Devices typically used for therapeutic or diagnostic
ultrasound operate at a frequency of between 1.6 and 10 MHz. These
devices can also be modified for use at lower frequencies. The
devices may optionally include a reservoir for an ultrasound gel,
which will typically have a sound coefficient like water, or a
reservoir for collecting analyte.
[0028] Although principally described herein as the combination of
ultrasound with an electrical field, chemical enhancers and
physical enhancers can also be used in combination with ultrasound.
Physical enhancers, as used herein, in addition to iontophoresis
and electroporation, include magnetic fields and mechanical
pressure. Ultrasound is used to permeabilize the skin followed by
the application of various force fields to provide additional
driving force for transdermal transport of molecules.
[0029] Electric Fields (Iontophoresis or Electroporation)
[0030] Application of ultrasound or electric current alone has been
shown to enhance transdermal drug transport and blood analyte
extraction. As discussed above, ultrasound-induced cavitation
occurring inside or outside the skin causes disordering of the SC
lipids. Oscillations of cavitation bubbles may also result in
significant water penetration into the disordered lipid regions.
This may cause the formation of aqueous channels through the
intercellular lipids of the SC, thus allowing permeants to
transport across the disordered lipid domains. Once able to diffuse
across the lipid domains, molecules may diffuse across
keratinocytes and hence across the entire SC.
[0031] Application of electric current enhances transdermal
transport by different mechanisms. First, application of an
electric field provides an additional driving force for the
transport of charged molecules across the skin and second, ionic
motion due to application of electric fields may induce convective
flows across the skin, referred to as electroosmosis. This
mechanism is believed to play a dominant role in transdermal
transport of neutral molecules during iontophoresis. Iontophoresis
involves the application of an electrical current, preferably DC,
or AC, at a current density of greater than zero up to about 1
mA/cm.sup.2. Typically, a constant voltage is applied since
resistance changes over time, usually in the range of between
greater than zero and four volts.
[0032] Attempts have been made to enhance the skin permeability
using electric current to achieve transdermal extraction of
glucose, as reported by Tamada, et al., Proceed. Intern. Symp.
Control. Rel. Bioact. Mater. 22, 129-130 (1995). Although these
attempts have been successful to a certain extent, the amounts of
glucose extracted by these methods are several orders of magnitude
lower than those which could be detected by the currently existing
biosensors. The mechanism of sonophoretic transdermal glucose
extraction is believed to be similar to that of sonophoretic
transdermal drug delivery. Specifically, application of
low-frequency ultrasound increases the skin permeability by
disordering its lipid bilayers which leads to the formation of
aqueous channels through the intercellular lipids of the SC. This
allows faster diffusion of glucose present in the interstitial
fluids across the permeabilized skin.
[0033] The application of ultrasound induces cavitation in the
keratinocytes of the stratum corneum. Furthermore, oscillations of
cavitation bubbles were shown to induce a partial disorder in the
skin lipid bilayer. In view of this, the cumulative effect of
ultrasound and electric field may also be related to cavitation
induced by ultrasound exposure. In order to test this hypothesis,
electric pulses (100 V across the skin, 1 ms exponential pulse
applied every minute) and ultrasound (3 MHz, 1.5 W/cm.sup.2) were
simultaneously applied to skin, as described below. It is known
that the cavitational effects vary inversely with ultrasound
frequency [Gaertner, W., Frequency dependence of ultrasonic
cavitation, J. Acoust. Soc. Am., 26:977-80 (1984)]. No significant
cavitational effects have been observed in fluids at high
ultrasound frequencies greater than 2.5 MHz. As a result, 2.5 MHz
is considered a reasonable estimate of the upper frequency limit
for the occurrence of cavitation in fluids at therapeutic
ultrasound intensities. Hence, if cavitation plays an important
role, the synergistic effect of ultrasound and electric field
should be nearly absent when 3 MHz ultrasound is used. Exposure to
ultrasound at 3 MHz (intensity =1.5 W/cm.sup.2) does not affect
transdermal transport by electric field pulsing. These results
indicate that cavitation may play a major role in the synergistic
effect of ultrasound and electric field pulsing.
[0034] Chemical Enhancers.
[0035] Lipid Bilayer Disrupting Agents.
[0036] Chemical enhancers have been found to increase drug
transport by different mechanisms. Chemicals which enhance
permeability through lipids are known and commercially available.
For example, ethanol has been found to increase the solubility of
drugs up to 10,000-fold (Mitragotri, et al. In Encl. of Pharm.
Tech.: Swarbrick and Boylan, eds. Marcel Dekker 1995) and yield a
140-fold flux increase of estradiol, while unsaturated fatty acids
have been shown to increase the fluidity of lipid bilayers
(Bronaugh and Maiback, editors (Marcel Dekker 1989) pp. 1-12).
[0037] Examples of fatty acids which disrupt lipid bilayer include
linoleic acid, capric acid, lauric acid, and neodecanoic acid,
which can be in a solvent such as ethanol or propylene glycol.
Evaluation of published permeation data utilizing lipid bilayer
disrupting agents agrees very well with the observation of a size
dependence of permeation enhancement for lipophilic compounds. The
permeation enhancement of three bilayer disrupting compounds,
capric acid, lauric acid, and neodecanoic acid, in propylene glycol
has been reported by Aungst, et al. Pharm. Res. 7, 712-718 (1990).
They examined the permeability of four lipophilic compounds,
benzoic acid (122 Da), testosterone (288 Da), naloxone (328 Da),
and indomethacin (359 Da) through human skin. The permeability
enhancement of each enhancer for each drug was calculated according
to .epsilon..sub.c/pg=P.sub.e/pg/P.sub.pg, where P.sub.e/pg is the
drug permeability from the enhancer/propylene glycol formulation
and P.sub.pg is the permeability from propylene glycol alone.
[0038] The primary mechanism by which unsaturated fatty acids, such
as linoleic acid, are thought to enhance skin permeabilities is by
disordering the intercellular lipid domain. For example, detailed
structural studies of unsaturated fatty acids, such as oleic acid,
have been performed utilizing differential scanning calorimetry
(Barry J. Controlled Release 6, 85-97 (1987)) and infrared
spectroscopy (Ongpipattanankul, et al., Phann. Res. 8, 350-354
(1991); Mark, et al., J. Control. Rel. 12, 67-75 (1990)). Oleic
acid was found to disorder the highly ordered SC lipid bilayers,
and to possibly form a separate, oil-like phase in the
intercellular domain. SC lipid bilayers disordered by unsaturated
fatty acids or other bilayer disrupters may be similar in nature to
fluid phase lipid bilayers.
[0039] A separated oil phase should have properties similar to a
bulk oil phase. Much is known about transport in fluid bilayers and
bulk oil phases. Specifically, diffusion coefficients in fluid
phase, for example, dimyristoylphosphatidylcholine (DMPC) bilayers
Clegg and Vaz In "Progress in Protein-Lipid Interactions" Watts,
ed. (Elsevier, NY 1985) 173-229; Tocanne, et al., FEB 257, 10-16
(1989) and in bulk oil phase Perry, et al., "Perry's Chemical
Engineering Handbook" (McGraw-Hill, NY 1984) are greater than those
in the SC, and more importantly, they exhibit size dependencies
which are considerably weaker than that of SC transport Kasting, et
al., In: "Prodrugs: Topical and Ocular Delivery" Sloan, ed. (Marcel
Dekker, NY 1992) 117-161; Potts and Guy, Pharm. Res. 9, 663-339
(1992); Willschut, et al., Chemosphere 30, 1275-1296 (1995). As a
result, the diffusion coefficient of a given solute will be greater
in a fluid bilayer, such as DMPC, or a bulk oil phase than in the
SC. Due to the strong size dependence of SC transport, diffusion in
SC lipids is considerably slower for larger compounds, while
transport in fluid DMPC bilayers and bulk oil phases is only
moderately lower for larger compounds. The difference between the
diffusion coefficient in the SC and those in fluid DMPC bilayers or
bulk oil phases will be greater for larger solutes, and less for
smaller compounds. Therefore, the enhancement ability of a bilayer
disordering compound which can transform the SC lipids bilayers
into a fluid bilayer phase or add a separate bulk oil phase should
exhibit a size dependence, with smaller permeability enhancements
for small compounds and larger enhancements for larger
compounds.
[0040] A comprehensive list of lipid bilayer disrupting agents is
described in European Patent Application 43,738 (1982), which is
incorporated herein by reference. Exemplary of these compounds are
those represented by the formula:
R--X
[0041] wherein R is a straight-chain alkyl of about 7 to 16 carbon
atoms, a non-terminal alkenyl of about 7 to 22 carbon atoms, or a
branched-chain alkyl of from about 13 to 22 carbon atoms, and X is
--OH, --COOCH.sub.3, --COOC.sub.2H, --OCOCH.sub.3, --SOCH.sub.3,
--P(CH.sub.3).sub.2O, COOC.sub.2H.sub.4C.sub.2H.sub.4OH,
--COOCH(CHOH).sub.4CH.sub.2O H, --COOCH.sub.2CHOHCH.sub.3,
COOCH.sub.2CH(OR")CH.sub.2OR", --OCH.sub.2CH.sub.2).sub.mOH,
--COOR', or --CONR'.sub.2 where R' is --H, --CH.sub.3,
--C.sub.2H.sub.5, --C.sub.2H.sub.7 or --C.sub.2H.sub.4OH; R" is
--H, or a non-terminal alkenyl of about 7 to 22 carbon atoms; and m
is 2-6; provided that when R" is an alkenyl and X is --OH or
--COOH, at least one double bond is in the cis-configuration.
[0042] Solubility Enhancers
[0043] Suitable solvents include water; diols, such as propylene
glycol and glycerol; mono-alcohols, such as ethanol, propanol, and
higher alcohols; DMSO; dimethylformamide; N,N-dimethylacetamide;
2-pyrrolidone; N-(2-hydroxyethyl) pyrrolidone, N-methylpyrrolidone,
1-dodecylazacycloheptan-2-one and other
n-substituted-alkyl-azacycloalkyl- -2-ones and other
n-substituted-alkyl-azacycloalkyl-2-ones (azones).
[0044] U.S. Pat. No. 4,537,776 to Cooper, incorporated herein by
reference contains a summary of prior art and-background
information detailing the use of certain binary systems for
permeant enhancement. European Patent Application 43,738, also
describes the use of selected diols as solvents along with a broad
category of cell-envelope disordering compounds for delivery of
lipophilic pharmacologically-active compounds. A binary system for
enhancing metaclopramide penetration is disclosed in UK Patent
Application GB 2,153,223 A, consisting of a monovalent alcohol
ester of a C8-32 aliphatic monocarboxylic acid (unsaturated and/or
branched if C18-32) or a C6-24 aliphatic monoalcohol (unsaturated
and/or branched if C14-24) and an N-cyclic compound such as
2-pyrrolidone or N-methylpyrrolidone.
[0045] Combinations of enhancers consisting of diethylene glycol
monoethyl or monomethyl ether with propylene glycol monolaurate and
methyl laurate are disclosed in U.S. Pat. No. 4,973,468 for
enhancing the transdermal delivery of steroids such as progestogens
and estrogens. A dual enhancer consisting of glycerol monolaurate
and ethanol for the transdermal delivery of drugs is described in
U.S. Pat. No. 4,820,720. U.S. Pat. No. 5,006,342 lists numerous
enhancers for transdermal drug administration consisting of fatty
acid esters or fatty alcohol ethers of C.sub.2 to C.sub.4
alkanediols, where each fatty acid/alcohol portion of the
ester/ether is of about 8 to 22 carbon atoms. U.S. Pat. No.
4,863,970 discloses penetration-enhancing compositions for topical
application including an active permeant contained in a
penetration-enhancing vehicle containing specified amounts of one
or more cell-envelope disordering compounds such as oleic acid,
oleyl alcohol, and glycerol esters of oleic acid; a C.sub.2 or
C.sub.3 alkanol and an inert diluent such as water.
[0046] Other chemical enhancers, not necessarily associated with
binary systems, include dimethylsulfoxide (DMSO) or aqueous
solutions of DMSO such as those described in U.S. Pat. No.
3,551,554 to Herschler; U.S. Pat. No. 3,711,602 to Herschler; and
U.S. Pat. No. 3,711,606 to Herschler, and the azones
(n-substituted-alkyl-azacycloalkyl-2-ones) such as noted in U.S.
Pat. No. 4,557,943 to Cooper.
[0047] Some chemical enhancer systems may possess negative side
effects such as toxicity and skin irritations. U.S. Pat. No.
4,855,298 discloses compositions for reducing skin irritation
caused by chemical enhancer-containing compositions having skin
irritation properties with an amount of glycerin sufficient to
provide an anti-irritating effect.
[0048] Combinations of Lipid Bilayer Disrupting Agents and
Solvents
[0049] Passive experiments without ultrasound with polyethylene
glycol 200 dilaurate (PEG), isopropyl myristate (IM), and glycerol
trioleate (GT) result in corticosterone flux enhancement values of
only 2, 5, and 0.8, relative to the passive flux from PBS alone.
However, 50% ethanol and LA/ethanol significantly increase
corticosterone passive fluxes by factors of 46 and 900. These
passive flux enhancements were due to (1) the increased
corticosterone solubility in the enhancers, and (2) interactions of
linoleic acid with the skin. Specifically, linoleic acid increased
the corticosterone permeability by nearly 20-fold over that from
50% ethanol alone. Therapeutic ultrasound (1 MHz, 1.4 W/cm.sup.2)
and the chemical enhancers utilized together produce corticosterone
fluxes from PBS, PEG, IM, and GT that are greater than the passive
fluxes from the same enhancers by factors of between 1.3 and 5.0,
indicating that the beneficial effects of chemical enhancers and
therapeutic ultrasound can be effectively combined. Ultrasound
combined with 50% ethanol produces a 2-fold increase in
corticosterone transport above the passive case, but increase by
14-fold the transport from LA/Ethanol. The combination of increased
corticosterone solubility in and permeability enhancement from
LA/ethanol and ultrasound yields a flux of 0.16 mg/cm.sup.2/hr,
13,000-fold greater than that from PBS alone. The permeability
enhancement resulting from the addition of linoleic acid to 50%
ethanol exhibits a clear size dependence, with the degree of
enhancement increasing with the size of the drug. The degree of
permeation enhancement achieved by adding linoleic acid to 50%
ethanol and applying ultrasound exhibits a similar size dependence.
These results suggest that linoleic acid and therapeutic
ultrasound, which are both lipid bilayer disordering agents, shift
the transport of lipophilic molecules from the passive regime to a
regime with a very weak size dependence.
[0050] Mechanical Forces.
[0051] Mechanical or Osmotic Pressure
[0052] The advantages of combining sonophoresis with physical
enhancers is not restricted to electrical current. Effects on
transdermal transport may also be observed between ultrasound and
pressure (mechanical or osmotic) as well as between ultrasound and
magnetic fields since the physical principles underlying the
enhancement are believed to be similar or the same. A pressure
gradient can be used to enhance convection (physical movement of
liquid) across the skin permeabilized by sonophoresis. This can be
particularly useful in transdermal extraction of blood analytes.
Application of pressure, for example, a vacuum or mechanical
pressure, to the skin pretreated by sonophoresis can result in
transdermal extraction of interstitial fluid which can be analyzed
to measure concentration of various blood analytes.
[0053] Magnetic Fields
[0054] Application of magnetic fields to the skin pretreated with
ultrasound may also result in a higher transport of magnetically
active species across the skin. For example, polymer microspheres
loaded with magnetic particles could be transported across the skin
using sonophoresis and magnetic fields.
[0055] The combination of sonophoresis with an electric field, and
optionally, any of these additional physical mechanisms for
enhanced transport provides the following advantages over
sonophoresis or the physical enhancers alone: i) It allows lowering
application times to deliver a given drug dose or extract a certain
amount of analytes compared to the required times in the presence
of ultrasound or one.of the other enhancers alone; ii) It reduces
the magnitude of the required ultrasound intensity and electric
current or pressure to achieve a given transdermal flux compared to
that required if, the enhancers were used alone; and iii) It can be
used to provide a better control over transdermal transport of
molecules compared to that obtained using an enhancer alone.
[0056] The combination of electrical field and ultrasound can be
applied to any membrane. The membrane can be skin, cell membrane,
cell wall and other biological as well as synthetic membranes. The
electric fields can be continuous, pulsed, having high as well as
low voltage. Application of ultrasound together with the electrical
fields results in higher flux compared to the flux observed with
electroporation or ultrasound alone. The onset time of transdermal
flux during electroporation can also be reduced by simultaneous
applications of ultrasound and electroporation. The effect is more
pronounced on less-charged molecules which by other enhancing
methods are hard to enhance (iontophoresis). The major limitation
of electroporation are the high voltages required in order to cause
significant effect. By using the combined effects of ultrasound and
electroporation, the intensity levels of the electrical fields will
be much lower and therefore no or less damage to the membranes will
be observed.
[0057] Drug Delivery
[0058] Drugs to be Administered.
[0059] Drugs to be administered include a variety of bioactive
agents, but are preferably proteins or peptides. Specific examples
include insulin, erythropoietin, and interferon. Other materials,
including nucleic acid molecules such as antisense and genes
encoding therapeutic proteins, synthetic organic and inorganic
molecules including antiinflammatories, antivirals, antifungals,
antibiotics, local anesthetics, and saccharides, can also be
administered.
[0060] The drug will typically be administered in an appropriate
pharmaceutically acceptable carrier having an absorption
coefficient similar to water, such as an aqueous gel.
Alternatively, a transdermal patch such as the one described in the
examples can be used as a carrier. Drug can be administered in a
gel, ointment, lotion, suspension or patch, which can incorporate
anyone of the foregoing.
[0061] Drug can also be encapsulated in a delivery device such as a
liposome or polymeric nanoparticles, microparticle, microcapsule,
or microspheres (referred to collectively as microparticles unless
otherwise stated). A number of suitable devices are known,
including microparticles made of synthetic polymers such as
polyhydroxy acids such as polylactic acid, polyglycolic acid and
copolymers thereof, polyorthoesters, polyanhydrides, and
polyphosphazenes, and natural polymers such as collagen, polyamino
acids, albumin and other proteins, alginate and other
polysaccharides, and combinations thereof. The microparticles can
have diameters of between 0.001 and 100 microns, although a
diameter of less than 10 microns is preferred. The microparticles
can be coated or formed of materials enhancing penetration, such as
lipophilic materials or hydrophilic molecules, for example,
polyalkylene oxide polymers and conjugates, such as polyethylene
glycol. Liposome are also commercially available.
[0062] Administration of Drug.
[0063] The drug is preferably administered to the skin at a site
selected based on convenience to the patient as well as maximum
drug penetration. For example, the arm, thigh, or stomach represent
areas of relatively thin skin and high surface area, while the
hands and feet are uneven and calloused. In the preferred
embodiment, drug is applied to the site and ultrasound and
electrical current applied immediately thereafter. Other enhancers
can be applied before, during or immediately after the ultrasound.
Chemical enhancers are preferable administered during or before
ultrasound.
[0064] Based on these calculations and the data in the following
examples, one can calculate the required dosage and application
regime for treatment of a patient, as follows. A typical diabetic
patient (70 Kg weight) takes about 12 Units of insulin three times
a day (total dose of about 36 Units per day: cited in `World Book
of Diabetes in Practice` Krall, L. P. (Ed), Elsevier, 1988). If
each insulin dose was to be delivered by sonophoresis in 1 hour,
the required transdermal flux would be 12 U/hour. Note that 1 unit
(1 U) of insulin corresponds approximately to 40 mg of insulin. The
transdermal patch area used in these calculations is 40 cm.sup.2
(the area of a transdermal FENTANYL.TM. patch [ALZA Corporation]).
The donor concentrations used in these calculations are 100 U/ml in
the case of insulin (commercially available insulin solution
[Humulin]), 3.times.10.sup.7 in the case of .gamma.-interferon
(typical concentration of interferon solution recommended by
Genzyme Corporation), and 3.times.10.sup.5 U/ml in the case of
erythropoietin [Davis, et al., Biochemistry, 2633-2638, 1987].
[0065] A typical .gamma.-interferon dose given each time to
patients suffering from cancer or viral infections is about
5.times.10.sup.6 U [(i) Grups, et al., Br. J. Med., 1989, 64 (3):
218-220, (ii) Parkin, et al., Br. Med. J., 1987, 294: 1185-1186].
Similar doses of .alpha.-interferon and .beta.-interferon have also
been shown to enhance the immune response of patients suffering
from viral infections and cancer (cited in `Clinical Applications
of interferons and their inducers`, Ed. Stringfellow D., Marcel
Dekker, New York, 1986). If this interferon dose was to be given by
sonophoresis in 1 hour, the required transdermal flux would be
5.times.10.sup.6 U/hour. Note that 1 unit of .gamma.-interferon
corresponds approximately to 1 pg of .gamma.-interferon.
[0066] A typical daily erythropoietin dose given subcutaneously to
anemic patients is about 400 U (cited in Subcutaneous
Erythropoietin, Bommer J., Ritz E., Weinreich T., Bommer G.,
Ziegler T., Lancet, 406, 1988). If this dose was to be delivered in
three steps, each involving sonophoresis for 1 hour, the
transdernal flux required would be about 140 U/hour. Note that 1
unit of erythropoietin corresponds approximately to 7.6 nanograms
of erythropoietin.
[0067] Optimal selection of ultrasound parameters, such as
frequency, pulse length, intensity, as well as of non-ultrasonic
parameters, such as ultrasound coupling medium, can be conducted to
ensure a safe and efficacious application using the guidelines
disclosed herein as applied by one of ordinary skill in the
art.
[0068] Measurement of Analytes
[0069] Analytes to be Measured.
[0070] A variety of analytes are routinely measured in the blood,
lymph or other body fluids. Measurements usually require making a
puncture in order to withdraw sample. Examples of typical analytes
that can be measured include blood sugar (glucose), cholesterol,
bilirubin, creatine, various metabolic enzymes, hemoglobin,
heparin, vitamin K or other clotting factors, uric acid,
carcinoembryonic antigen or other tumor antigens, and various
reproductive hormones such as those associated with ovulation or
pregnancy. Transdermal drug delivery, in combination with the
non-invasive blood analyte measurements, may be used to formulate
self-regulated drug delivery methods which provide a close control
of the blood concentrations, minimal pain, and better patient
compliance. Non-invasive blood analysis method includes extraction
of various analytes from the skin's interstitial fluids (where the
analytes are present at a concentration proportional to the blood
concentration) across the skin into a patch, solution or gel, where
their concentration can be measured using biosensors. This method
of blood analyte measurements should be particularly useful in the
case of diabetic patients who require multiple daily blood glucose
measurements.
[0071] Measurement of Analytes.
[0072] The ultrasound is applied to the skin at the site where the
sample is to be collected. A reservoir or collecting container is
applied to the site for collection of the sample, which is then
measured using standard techniques. The ultrasound conditions are
optimized as in the case for drug delivery, to maximize analyte
recovery, while maintaining the relative levels of the analyte to
other components of the sample. Chemical and/or physical enhancers
are applied to the site before, during and after the ultrasound,
preferably during or before the ultrasound.
[0073] The present invention will be further understood by
reference to the following non-limiting examples.
EXAMPLE 1
[0074] Comparison of Drug Transfer Through Skin using Ultrasound or
Electrical Field Alone or in Combination.
[0075] Material and Methods
[0076] A. Materials
[0077] Full thickness of human cadaver skin (obtained from local
hospitals) was heat stripped by immersion in 60.degree. C. water
for two minutes followed by the removal of the epidermis. The skin
was then stored in a humidified chamber (95% relative humidity) at
4.degree. C. The heat-stripped human epidermis was placed in a
custom-made side-by-side permeation chamber, skin area of 0.64
cm.sup.2, designed to adapt an ultrasound transducer at the donor
side. The donor compartment was filled with a 1 mM solution of
calcein (MW 623, electric charge -4; Sigma Chemicals) (CA) and 1 mM
sulphorhodamine (MW 607, electric charge -1; Sigma Chemical) (SR)
in 150 mM Phosphate Buffer Saline (PBS; Sigma Chemicals).
[0078] The ultrasound probe was inserted into the donor
compartment. The direction of the ultrasound wave was perpendicular
to the membrane surface. The stratum comeum was facing the donor
compartment. Both donor and receptor compartments were filled with
degassed phosphate buffer saline (PBS) pH=7.4. The temperature was
followed to be in the range of 22.+-.2.degree. C. SR and CA were
added to the donor compartment to provide concentration of 1 mM CA
and 1 mM SR. Fresh PBS was continuously pumped into the receptor
compartment at 0.8 ml/min from a reservoir.
[0079] B. Fluorescence measurements
[0080] The fluorometer was set up for dual wavelength measurements
(excitation wavelength=488 nm, emission wavelength=515 nm
(calcein), and excitation wavelength=586 nm, emission
wavelength=607 nm (sulphorhodamine)). The sample cuvette of the
fluorometer was sealed but for two openings that were provided for
the flow of receiver fluid through it. A small custom-made electric
stirrer was installed in the cuvette so that there were no stagnant
zones in it. Care was taken to avoid any obstruction of the
excitation beam by the stirrer. Transdermal calcein and
sulphorhodamine flux was calculated from the fluorescence readings
by taking into account parameters such as flow rate, receiver
compartment volume, and fluorometer caveat volume. The effluent
from the receptor compartment was pumped through a
spectrofluorometer (Fluorolog-II-system F112AI SPEX-industries,
Edison, N.J.) where the fluorescence of calcein and sulphorhodamine
was separately measured twice every minute. The excitation for CA
is 488 nm and for SR 586 nm, the measurement for CA was at 515 mn
and for SR 607 nm. The receptor was mixed by an electromechanical
stirrer. The fluorescence measurements were deconvoluted to
calculate the CA and SR flux.
[0081] C. Application of Ultrasound
[0082] Two studies were conducted. In the first, two ultrasound
sources were utilized:
[0083] i. 20 KHz Sonics and Materials (250 W) with a probe surface
area of 0.25 cm.sup.2.
[0084] ii. 1 MHz Sonopuls Therapeutic device with probe surface
area of 0.8 cm.sup.2. Pulsed and continuous modes were evaluated
below 2 W/cm.sup.2 for the continuous mode and 2-3 W/cm.sup.2
pulsed (20% duty-cycle). The distance of the probe tips from the
skin was 3 cm for the 20 KHz and 4 cm for the 1 MHz.
[0085] In the second study, ultrasound was applied under
therapeutically approved conditions (1.4 W/cm.sup.2, 1 MHz and 3
MHz, continuous) using a sonicator (Sonopuls 463, Henley
International) for various exposure times up to 1 hour. The
ultrasound transducer was located at a distance of about 3 cm from
the skin.
[0086] D. Electroporation
[0087] One Ag/AgCl electrode (In vivo metric, Healdsburg, Calif.)
was located in the donor and one in the receptor compartment, so
that the distance of electrodes from the skin was equal in both the
compartments (about 8 mm). Voltage pulses were applied using a
pulse generator (ECM 600, BTX, San Diego, Calif.) across the
electrodes such that the positive electrode was always in the
receptor compartment. This provided an electric driving force for
calcein and sulphorhodamine (both negatively charged) to transport
across the skin. The voltage applied to the electrodes divides
between the saline and the skin. The voltage drop across the skin
was estimated using the measured electrical resistance of the skin
and saline. The magnitude as well as the length of the voltage
pulses was varied over a wide range in order to investigate their
effect on transdermal transport.
[0088] In the first set of experiments (FIGS. 1A, 1B, 2A), a
voltage divider of 10:40 ohm was used to provide a fixed time
constant (exponential shape pulse). The maximum pulsing voltage in
all experiments was 750 volts across the chamber (refers to a
voltage drop across the skin of 210-230 volts). The pulse rate was
1 pulse/min for 60 minutes, controlled by a computer.
[0089] In the second set of studies (FIGS. 1C, 2B and 2C, 3), the
electric field (100 V) was applied across the skin, exponentially
decaying pulse with a time constant (T) of 1 millisecond, one pulse
applied every minute.
[0090] In order to assess the stability of these molecules during
electroporation, calcein and sulphorhodamine solutions (1 mM each)
were exposed to electroporating conditions similar to those used in
this study. No difference between the intensity of their
fluorescence before and after exposure to electric fields could be
detected. In addition, these molecules are stable up to a
temperature of 100.degree. C. (measured in terms of fluorescence).
When these molecules are degraded, they do not fluoresce. In
general, these molecules have been found to be very stable against
many physico-chemical changes.
[0091] E. Measurements of Passive Electric Skin Properties
[0092] A second pair of electrodes (same type as above) was used
for monitoring the passive electrical properties (specifically,
electrical resistance). Since the electrical resistance of the skin
is a good indicator of its barrier properties, the skin resistance
was measured before, during and after the experiments. The effect
of electroporation and ultrasound separately and together on skin
electrical resistance was determined. If the electrical resistivity
before the application of either ultrasound or electroporation was
lower than 20 k.OMEGA.-cm.sup.2 or if any significant passive
calcein or sulphorhodamine transdermal flux was observed (that is,
J greater than 0.002 .mu.g/cm.sub.2/h (the detection limit)), the
skin piece was considered leaky and replaced by a new piece.
[0093] Results and Discussion
[0094] A. Application of Ultrasound Enhances the Efficacy of
Electric Field.
[0095] The results of the first study are shown in FIG. 1A. FIG. 1A
shows the time variation flux of SR which permeated the skin with
time. After 400 sec of passive diffusion, pulsed ultrasound (1 MHz,
20% duty cycle, 2.5-2.9 W/cm.sup.2) was turned on for 2750 sec. The
ultrasound was turned off at 2750 sec. High voltage pulsing was
turned on at 6900 sec for 1 hour (10,500 sec end of electroporation
pulsing). Ultrasound (1 MHz, 0.8 cm.sup.2 20% duty cycle, 2.5-2.9
W/cm.sup.2) was turned on again at 14,310 sec, electroporation
(same condition) was turned on again at 15,200 sec while the pulsed
ultrasound was on. At 16,440 sec the ultrasound wave was changed
from pulsed to continuous while the electroporation continued. The
experiment was terminated at 20,040 sec. The experimental procedure
is summarized in table 1 below.
1TABLE 1 Conditions used for determining effect of ultrasound and
electroporation Description of the From (sec) To (sec) transdermal
transport 0 400 passive diffusion 400 3150 pulsed ultrasound 3150
6900 passive diffusion 6900 10500 electroporation 10500 14310
passive diffusion 14310- 15200 pulsed ultrasound 15200- 16400
electroporation + pulsed ultrasound 16440- 20040 electroporation +
continuous ultrasound
[0096] FIGS. 1B and 1C show the effect of simultaneous application
of ultrasound (1 MHz, 1.4 W/cm.sup.2, continuous application) and
electric field (100 V across the skin, exponentially decaying pulse
with a time constant (.tau.) of 1 millisecond, one pulse applied
every minute) on the transdermal transport of calcein and
sulphorhodamine respectively. The passive transdermal transport (in
the absence of ultrasound and electric field) is below the
detection limit and is not shown in FIG. 1B or 1C. Application of
ultrasound alone does not enhance the flux of calcein or
sulphorhodamine. However, application of ultrasound enhanced
steady-state transdermal flux of both calcein and sulphorhodamine
during electric field pulsing. The enhancement is quantitatively
defined as the amount of calcein or sulphorhodamine transported in
the presence of ultrasound-electric field pulsing to that in the
presence of electric field pulsing alone. This ratio is 2 in the
case of calcein (FIG. 1B), and 3 in the case of sulphorhodamine
(FIG. 1C). Application of ultrasound also reduced transdermal
calcein transport lag time, defined as the time required to reach
the steady state, from a typical value of 15 minutes in the
presence of electric field alone to about 9 minutes in the presence
of ultrasound and electric field.
[0097] Similar effects of ultrasound on transdermal transport of SR
and CA during electroporation can be also seen in FIGS. 2A and 2B
which present the flux of CA (FIG. 2A) and SR (FIG. 2B) in
experiments where the skin samples were exposed continuously to
electroporation and continuous ultrasound (1 MHz, 0.8 cm.sup.2, 2
W/cm.sup.2) (o) and controls (x) where the skin was exposed to
electric fields alone. The possible mechanism for this phenomena
might be that the electrical pulsing creates short term pores in
the skin while ultrasound is forcing the solutes through these
pores.
[0098] In order to quantitatively estimate the reduction in the
required pulsing voltages by simultaneous application of ultrasound
and electric field, transdermal sulphorhodamine transport was
measured in the presence as well as absence of ultrasound (1 MHz,
1.4 W/cm.sup.2) and electric field (voltage across the skin
increased from 20 V to 150 V in steps of 5 V every 30 minutes, 1
millisecond exponential pulse applied every minute).
[0099] FIG. 3 shows the variation of transdermal sulphorhodamine
flux with voltage across the skin in the presence (O) as well as in
the absence (X) of ultrasound. The transdermal sulphorhodamine flux
is nearly zero as long as the voltage is below the threshold value
and thereafter increases linearly with voltage. The threshold
voltage for this pulsing protocol can be estimated by measuring the
intercept of the linear variation of flux with voltage on the
voltage axis. In the absence of ultrasound, this threshold is about
53.+-.3 V and that in the presence of ultrasound is about 46.+-.3
V, indicating that application of ultrasound slightly reduces the
threshold pulsing voltage. FIG. 3 also shows that the transdermal
sulphorhodamine flux at various pulsing voltages is always higher
in the presence of ultrasound. Thus, the pulsing voltage required
to achieve a given transdermal flux is smaller in the presence of
ultrasound. For example, to achieve a transdermal sulphorhodamine
flux of 0.15 .mu.g/cm.sup.2/hr, the required voltage is about 95 V
in the absence of ultrasound and 75 V in the presence of
ultrasound.
[0100] Cavitation may play a two-fold role in enhancing the effect
of electric field on transdermal transport. First, oscillations of
cavitation bubbles induce partial structural disordering of the
skin's lipid bilayers. Since the electrical resistance of the
disordered bilayers is likely to be smaller than that of the normal
lipid bilayers, the applied electric field may concentrate
preferentially across the normal bilayers. This may decrease the
threshold electroporating voltage for transdermal transport of
calcein and sulphorhodamine. Application of ultrasound reduces the
threshold pulsing voltage from about 53.+-.3 V in the absence of
ultrasound to about 46.+-.3 V in the presence of ultrasound (a
reduction of about 12%). This number is comparable to an
independent estimate of the fraction of SC bilayer disordered by
ultrasound application (15%).
[0101] The oscillations of cavitation bubbles may also induce
convection across the skin. In order to assess the role of
convection in the synergistic effect of ultrasound and electric
field, transdermal calcein and sulphorhodamine transport was
measured sequentially in the presence of electric field alone,
ultrasound and electric field, ultrasound alone and in the absence
of ultrasound and electric field. The results of these sequential
procedure are shown in FIG. 4. Results from a single experiment are
shown to depict the shape of the curves clearly. Note the change in
the transdermal flux at 1 and 1.5 hours when electric field and
ultrasound is turned OFF respectively. If electrophoresis plays an
important role in calcein and sulphorhodamine transport, the
transdermal flux is likely to decrease rapidly after electric
fields is turned OFF. On the other hand, if cavitation-induced
convection plays an important role, transdermal flux would rapidly
decrease after turning ultrasound OFF. Indeed, calcein flux
decreases rapidly after turning electric field OFF (1 hour) and
achieves a value comparable to the background flux. When ultrasound
is turned OFF at 1.5 hours, calcein flux further decreases by a
small amount (compared to the reduction after turning electric
field OFF at 1 hour) and thereafter it remains nearly at the
background level. This suggests that calcein transport is mainly
driven by electric forces. On the other hand, convection appears to
play an important role in transdermal sulphorhodamine transport in
the presence of ultrasound and electric field because the
sulphorhodamine flux did not decrease rapidly after turning
electric fields OFF, but decreased instantaneously after turning
ultrasound OFF at 1.5 hours. The total decrease in the transdermal
sulphorhodamine flux after turning the electric field OFF (that is,
between a period of 1 and 1.5 hours) is comparable to the
instantaneous decrease in its value after turning ultrasound OFF at
1.5 hours. This suggests that both electric field and
ultrasound-generated convection may play an important role in
transdermal sulphorhodamine transport. This difference in the
behavior of calcein and sulphorhodamine is presumably because
calcein possesses a much larger charge (4) compared to
sulphorhodamine (-1). In this respect, it is important to note that
the transdermal transport of calcein and sulphorhodamine in the
presence of electric field alone also differs significantly.
Calcein transport increases rapidly and achieves a steady state
within 15 minutes. Sulphorhodamine flux, however, increases
continuously with time over the experimental duration. This
difference in the behavior of calcein and sulphorhodamine flux may
also be attributed to the lower charge on sulphorhodamine, as the
transport during the electrical pulses is driven by
electrophoresis.
[0102] The combined effect of electroporation and ultrasound on
transdermal flux in all experiments was higher for SR than CA,
suggesting that the additional enhancement by ultrasound is more
effective on less charged molecules. The effect of ultrasound was
observed on both the lag time and the steady state flux for the two
molecules.
[0103] In summary, electroporation of the skin resulted in a very
significant increase in SR permeability. The phenomenon was
observed also on repeated application of electroporation, but the
enhancing effect was only slightly higher. Application of
ultrasound without electroporation did not result in enhanced flux.
The very pronounced increase in permeability was observed when the
skin was exposed to the combined effect of ultrasound and
electroporation (more than twice the flux value observed with
electroporation without ultrasound). The combined effect of
ultrasound and electroporation was also observed in additional
exposures of the same skin specimens.
EXAMPLE 2
[0104] Determination of Effect of Ultrasound on Skin.
[0105] The following experiment was measured in order to assess
whether application of ultrasound induces any irreversible change
in the skin structure. Human skin pieces were exposed to electric
field alone (100 V across the skin, exponentially decaying pulse
with a time constant (.tau.) of 1 millisecond, one pulse applied
every minute), then simultaneously to ultrasound (1 MHz, 1.4
W/cm.sup.2)-electric field and again to electric field alone. A
comparison of sulphorhodamine transport due to the electric field
alone, before and after the simultaneous electric field-ultrasound
treatment, indicated that the flux returns to a near baseline
value, suggesting that the application of ultrasound did not induce
any irreversible alteration in the barrier properties of skin. The
recovery was also supported by electric resistance measurements
indicating that application of ultrasound did not cause any
irreversible change in the electrical resistance of the skin.
[0106] Modifications and variations of the present invention will
be obvious to those skilled in the art from the foregoing detailed
description, and are intended to come within the scope of the
appended claims.
* * * * *